Evaluation of Mesopic Visual Acuity and Patient Satisfaction Following Ray-Tracing-Guided LASIK

NCT07790185 | Recruiting Phase 4 FDA Device

• 1 other identifier: 101390595
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

To provide comprehensive evaluation of WaveLight® Plus technology by assessing impact on both functional low-light vision and patient reported outcomes

Conditions

Astigmatism; Myopia

Outcome Measures

Primary Outcomes (2)

• Establish non-inferiority of the post-operative uncorrected mesopic distance visual acuity MVA (UC-MVA, monocular) at 6 months to the pre-operative Best Spectacle-Corrected MVA (BSC-MVA, monocular), assessed in logMAR units

  Baseline compared to 6 month post operative visit

• Patient reported outcome of overall satisfaction with vision, measured using the Patient Reported Outcomes with LASIK - Satisfaction Survey (#1 of PROWL-SS, 0-100)

  Baseline compared to 6 month post operative visit

Secondary Outcomes (6)

• Satisfaction with night vision (modified based on #1 of PROWL-SS, 0 - 100) at baseline and 6-month post-op

  Baseline compared to 6 month post operative visit

• Difficulty driving at night (from PROWL, Top-2-box) at baseline and 6-month post-op

  Baseline compared to 6 month post operative visit

• Frequency of starbursts or halo that bother you (PROWL, Top-2-box) at baseline and 6-month post-op

  Baseline compared to 6 month post operative visit

• Mesopic contrast sensitivity measured with and without glare (binocular) at baseline and 6-month post-op+

  Baseline compared to 6 month post operative visit

• Uncorrected Distance Visual Acuity under photopic conditions at 6-month post-op

  Baseline compared to 6 month post operative visit

Other Outcomes (3)

• Other night vision questions and VND-Q (item 1-4, Top-2-box of each) at baseline and 6-month post-op

  Baseline compared to 6 month post operative visit

• Other domain scores of PROWL-SS (glare, halo, starbursts)

  Baseline compared to 6 month post operative visit

• BOSA tear film analysis at baseline and 6-month post-op

  Baseline compared to 6 month post operative visit

Study Arms (1)

WaveLight Plus

EXPERIMENTAL

Device: Wavelight Plus

Interventions

Wavelight Plus DEVICE

comprehensive evaluation of WaveLight® Plus technology by assessing impact on both functional low-light vision and patient reported outcomes

WaveLight Plus

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects ages 18 to 45 years old.
• Stable refraction (within ± 0.50 D) as determined by manifest refraction spherical equivalent for a minimum of 12 months prior to surgery or stability as determined by the investigator.
• Myopia with or without astigmatism and MRSE within the range of indications for wavelight plus (myopia up to -8.00D, astigmatism up to -3.00D, S.E. more than -1.00 and up to -9.00D)
• Best corrected distance visual acuity (BCDVA) of 20/20 or better (≥83 letters) in each eye.
• Subjects who have elected to undergo bilateral LASIK targeted for emmetropia.
• Subjects must be able and willing to return for scheduled follow-up examinations after surgery.
• Subjects must be able to read, understand and provide written informed consent on the Institutional Review Board (IRB) approved Informed Consent Form (ICF) and provide authorization as appropriate for local privacy regulations.
• Mesopic pupil size ≥4.5mm
• Less than 0.75D spherical equivalent differences between Sightmap measured refraction SE and the subjective manifest refraction (MRSE)
• Subjects who regularly drive at night and expect to continue night driving throughout the duration of the study, as determined by investigator assessment

You may not qualify if:

• Pregnant or nursing women, or those who plan to become pregnant over the course of this clinical study or have another condition with associated fluctuation of hormones that could lead to refractive changes.
• Dry eye syndrome that is unable to be controlled with ocular lubricant(s) or medication(s) and which may confound study outcomes in the opinion of the Investigator.
• Previous corneal ocular surgery
• History of evidence of active or inactive corneal disease or retinal vascular disease, keratoconus or glaucoma or glaucoma suspect.
• Serious acute, chronic, or systemic, non-ophthalmic disease or illness that would increase the operative risk, confound the outcome(s) of the study or which may preclude study completion (e.g., immunocompromised, connective tissue disease, clinically significant atopic disease, uncontrolled diabetes, etc.), in the opinion of the Investigator.
• Ocular condition (other than high myopia) that may predispose the subject to future complications, in the opinion of the Investigator.
• Subjects who, in the judgment of the Investigator, present any emotional, physiological, or anatomical condition which may preclude participation in this study or provide an inappropriate landscape for the intended study treatment.
• Patients with a calculated residual stromal depth \<250 um

Sponsors & Collaborators

• Vance Thompson Vision: lead
• Alcon, a Novartis Company: collaborator

Study Sites (1)

Vance Thompson Vision

Sioux Falls, South Dakota, 57108, United States

RECRUITING

MeSH Terms

Conditions

Astigmatism; Myopia

Condition Hierarchy (Ancestors)

Refractive Errors; Eye Diseases

Central Study Contacts

Kayla Karpuk, OD

CONTACT

605-361-3937; kayla.karpuk@vancethompsonvision.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 24, 2026
• First Posted: August 27, 2026
• Study Start: April 20, 2026
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): November 1, 2027
• Last Updated: August 27, 2026

Record last verified: 2026-08

Locations

US (1)